NCT02030964 2025-02-17
DFMO
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
Clinical Trials
8 trialsNCT01059071 2024-08-06
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Milton S. Hershey Medical Center
Phase 1 Completed
NCT02395666 2024-08-06
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
Phase 2 Completed
NCT00204789 2019-12-16
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
University of Wisconsin, Madison
Phase 2 Completed
NCT00006079 2018-10-25
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00021294 2018-09-11
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
University of Arizona
Phase 2 Completed
NCT00006101 2018-05-14
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
University of California, Irvine
Phase 2 Completed
NCT00003076 2012-12-19
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
University of Michigan Rogel Cancer Center
Phase 2 Completed